CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Cisplatin +2 moredrug
Likely dose
Cisplatin 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00586846
NCT00586846Phase 2Completed
CompareCT.gov

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 7, 2008·Updated Jan 20, 2016

In Brief

A Phase 2 clinical trial evaluating Cisplatin, Doxorubicin, and 1 other intervention for Osteosarcoma. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study is designed to test the safety and feasibility of the simultaneous administration of a biphosphonate with chemotherapy for the treatment of osteosarcoma in newly diagnosed patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteosarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2008
Enrollment StartJul 1, 2003
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 18.5 years ago

Interventions

Cisplatindrug

Cisplatin 120 mg/m\^2

Doxorubicindrug

75mg/m\^2

Methotrexatedrug

Methotrexate 12g/m\^2